Dana-Farber Cancer Institute in Massachusetts, US, has obtained approval from the Massachusetts Public Health Council to build a cancer hospital in Boston.
The 300-bed hospital is intended to serve as a space for clinical collaboration with Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical Faculty Physicians (HMFP).
Go deeper with GlobalData
The facility will occupy the current site of the Joslin Diabetes Center on Brookline Avenue, joining onto both BIDMC and Dana-Farber Cancer Institute.
It aims to provide a cohesive care experience for patients by creating a unified campus.
Dana-Farber Cancer Institute president and CEO Benjamin Ebert said: “We appreciate the ongoing work of our regulatory agencies, including the Department of Public Health, to ensure that world-class cancer care is available to everyone who needs it.
“This is an extraordinary opportunity for Boston and the Commonwealth. While the incidence of cancer is rising, what we do now will determine our ability to meet the pace of the disease here and across the region.”
The collaboration with BIDMC and HMFP will bring together a range of specialist clinicians, including surgical oncologists and onco-cardiologists, aided by a nursing team with specialised training in oncology.
While Dana-Farber will own and operate the hospital, the joint clinical teams will follow a patient care model that aims to streamline treatment access, reduce barriers to care and promote the availability of clinical trials and advanced treatment options.
An independent cost analysis by the Massachusetts Department of Public Health has indicated that the new cancer hospital will contribute to the delivery of cost-effective care within the Commonwealth.
In addition, a cost and market impact review from the Health Policy Commission has suggested that Dana-Farber and BIDMC’s collaborative efforts will reduce treatment costs for inpatients.
In September 2023, Dana-Farber and BIDMC partnered to build an inpatient hospital for adult cancer patients in Boston.
